Teleflex updates on Q2 earnings, FDA clearances, acquisitions, deals & study data.

This study, when combined with the 2 earlier independent studies by the same team, shows that using an Arrow CVC with antimicrobial protection from Teleflex makes sense from many perspectives. This study is further evidence that using an unprotected catheter may put both patients and a hospital’s bottom line at unnecessary risk. The Arrow CVC with Arrow+ard Technology has been repeatedly shown to improve patient safety even when the risk of infection is low, and it more than pays for itself in the process,” vascular access division prez Jay White said in a prepared statement. The Arrow catheter also displayed lower CVC related costs compared to unprotected catheters, Teleflex said, with the cost being significantly lower per-day in comparison. “Our research had previously established that the antimicrobial catheter justified itself both clinically and in cost-effectiveness when inserted in sites associated with higher CRBSI rates. Would the same thing be true if the catheter was used in sites with a low risk of infection? The answer is ‘yes’ according to our data, making the protected catheter a prudent choice in many circumstances – especially for hospitals that have an above-benchmark rate of CRBSIs,” study head Dr. Leonardo Lorente of Tenerife, Spain’s Hospital Universitario de Canarias said in a press release. Another study, involving the company’s Arrow EZ-IO intraosseous vascular access sytem, compared the system agai...
Source: Mass Device - Category: Medical Equipment Authors: Tags: 510(k) Business/Financial News Cardiovascular Catheters Food & Drug Administration (FDA) MassDevice Earnings Roundup Mergers & Acquisitions Regulatory/Compliance Surgical Teleflex Source Type: news